BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, September 25, 2023
Home » Blogs » BioWorld Perspectives » Caught in Its Own Snare

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

Caught in Its Own Snare

July 16, 2012
By Mari Serebrov
No Comments

A hunter walks into a bar and says, “Did you hear the one about the FDA?”

“You mean the time it shot itself in the foot?” the bartender responds.

“The left foot or the right foot?” another hunter asks, wiping the beer froth from his mouth.

“What difference does that make?” the first hunter asks.

“I want to know if it’s the one I’ve heard before. Or if this is a new one.”

The first rule of thumb for hunters is to know what they’re doing. Otherwise, they might shoot themselves in the foot – or worse. The second is to get a valid hunting license. The third is to make sure they don’t target animals that aren’t in season.

The FDA broke those rules when it set out to track down a few scientists who it claimed had gone rogue by sharing concerns about device approvals with members of Congress and the White House. The agency tried to get a license. “No way,” it was told by the Office of Inspector General. “That dog just won’t hunt.”

The FDA, being the FDA, decided it didn’t need a license. It loaded its guns, set its snares and hired a document-hunting outfitter to help it bag its trophies. The agency reportedly gave the guide a list of the targeted species and provided scents to sniff out along the document trail. Those smells led to the media and a few hound dog congressmen and their staffs – species that should be on every federal agency’s “do not hunt” list.

The hunters at the FDA justified their poaching by saying the scientists were fair game because they were leaking information, some of which could be proprietary. Those leaks could damage the agency, its mission and its reputation, they reasoned.

Intent on catching the big game and defending its unlicensed hunt, the FDA forgot to set the safety on its weapons. As a result, the outfitter tripped and misfired, publicly posting a database with the contents of all the document tracking, including the proprietary stuff and the scents used to mark the trail. The shot hit the FDA square in the mouth and left a gaping, oozing wound in its reputation.

Now, the FDA’s the prey. And these days, it’s looking a lot like a limping deer caught in the intensely hot headlights of Congress and the media.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing